AI Article Synopsis
- Endothelins, particularly Endothelin-1 (ET1) and Endothelin-3 (ET3), are key peptides involved in blood vessel constriction and have various roles in the body, including potential neuroprotective functions.
- In this study, researchers focused on comparing ET3 plasma levels in multiple sclerosis (MS) patients and healthy individuals, as well as examining changes in ET1 and ET3 levels during different phases of MS.
- Findings indicated that ET3 levels in MS patients changed over time, suggesting a possible role for ET3 in neuroprotection and the modulation of immune responses in the context of MS.
Article Abstract
Endothelins are powerful vasoconstrictor peptides that play numerous other roles. Endothelin-1 (ET1) is the principal isoform produced by the endothelium in the human cardiovascular system. Endothelin-3 (ET3) and its rPptor affinity have been demonstrated to support neuronal repair mechanisms throughout life. In multiple sclerosis (MS), the role of vasoactive peptides are not well defined. Here we focus on ET3, specifically the plasma levels between MS patients and healthy subjects. Furthermore, we evaluated the changes in ET1 and ET3 plasma levels during different disease phases, the correlation between ET3 and cerebral circulation time, and the relationship between ET1 and ET3. In MS patients, the ET3 plasma levels were altered in a time-dependent manner. These results could support a putative role of ET3 in neuroprotection and/or neuroimmune modulation over time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/bmc-2020-0012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity.
Nat Commun
July 2023
Wake Forest Institute for Regenerative Medicine, Fetal Research and Therapy Program, Wake Forest School of Medicine (WFSOM), Winston Salem, NC, USA.
Hemophilia A is the most common X-linked bleeding disorder affecting more than half-a-million individuals worldwide. Persons with severe hemophilia A have coagulation FVIII levels <1% and experience spontaneous debilitating and life-threatening bleeds. Advances in hemophilia A therapeutics have significantly improved health outcomes, but development of FVIII inhibitory antibodies and breakthrough bleeds during therapy significantly increase patient morbidity and mortality.
View Article and Find Full Text PDFInsights into Endothelin-3 and Multiple Sclerosis.
Biomol Concepts
June 2020
Neurology and Neurophysiology Unit, Dpt. of Neurology and Human Movement Sciences, University Hospital of Siena, Santa Maria alle Scotte, Viale Bracci 2 53100 Siena, Italy.
Article Synopsis
- Endothelins, particularly Endothelin-1 (ET1) and Endothelin-3 (ET3), are key peptides involved in blood vessel constriction and have various roles in the body, including potential neuroprotective functions.
- In this study, researchers focused on comparing ET3 plasma levels in multiple sclerosis (MS) patients and healthy individuals, as well as examining changes in ET1 and ET3 levels during different phases of MS.
- Findings indicated that ET3 levels in MS patients changed over time, suggesting a possible role for ET3 in neuroprotection and the modulation of immune responses in the context of MS.
High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells.
Blood Adv
October 2019
Division of Medical Genetics and.
We developed an in vivo hematopoietic stem cell (HSC) transduction approach that involves HSC mobilization from the bone marrow into the peripheral bloodstream and the IV injection of an integrating, helper-dependent adenovirus (HDAd5/35) vector system. HDAd5/35 vectors target human CD46, a receptor that is abundantly expressed on primitive HSCs. Transgene integration is achieved by a hyperactive Sleeping Beauty transposase (SB100x) and transgene marking in peripheral blood cells can be increased by in vivo selection.
View Article and Find Full Text PDFPreclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Hum Gene Ther
October 2018
1 Aflac Cancer and Blood Disorders Center, Department of Pediatrics, School of Medicine, Emory University , Atlanta, Georgia; Christian Medical College, Vellore, India .
Genetically modified, autologous hematopoietic stem and progenitor cells (HSPCs) represent a new class of genetic medicine. Following this therapeutic paradigm, we are developing a product candidate, designated CD68-ET3-LV CD34, for the treatment of the severe bleeding disorder, hemophilia A. The product consists of autologous CD34 cells transduced with a human immunodeficiency virus 1-based, monocyte lineage-restricted, self-inactivating lentiviral vector (LV), termed CD68-ET3-LV, encoding a bioengineered coagulation factor VIII (fVIII) transgene, termed ET3, designed for enhanced expression.
View Article and Find Full Text PDFReduced Hemoglobin Levels Combined with an Increased Plasma Concentration of Vasoconstrictive endothelin-1 are Strongly Associated with Poor Outcome During Acute Ischemic Stroke.
Curr Neurovasc Res
June 2019
The Department of Neurology, Pomeranian Medical University, Szczecin, Poland.
The association of poor outcome and mortality with low levels of hemoglobin (Hb) and hematocrit (HcT) in patients admitted after acute Ischemic Stroke (IS) was recently demonstrated. The mechanisms behind this still remain unclear. Our study aims to find out whether mRNA expressions and plasma concentrations of endothelin-1 (ET-l), endothelin-2 (ET-2) and endothelin-3 (ET-3) remain different in IS sufferers with low HcT and Hb levels in comparison with those whose HcT i Hb levels during a severe IS episode remain within the norm.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!